You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., Oct. 31, 2017 /PRNewswire/ -- Astellas recently announced Nate Crisel has been promoted to vice president, Real World Informatics & Analytics (RWI), reporting to Chikashi Takeda, chief financial officer, effective Oct. 1, 2017.
"Nate's background at Astellas includes roles in New Product Analysis and nearly four years at our Tokyo headquarters in Product and Portfolio Strategy and Corporate Planning divisions," said Takeda. "It was in his role in Corporate Planning where he initiated the idea of having the RWI Center of Excellence. He then proceeded to build the organization from scratch to its current state."
Crisel will continue to be responsible for overseeing the RWI division, a central function accountable for expanding efficient, effective and compliant use of healthcare data across the entire Astellas value chain.
Prior to joining Astellas in 2008, Crisel served as an analytical chemist and pharmaceutical development project manager at Eli Lilly and Company (Lilly). After Lilly, he held roles ranging from business development and executive leadership at biotech start-ups, including Embedded Concepts, LLC, and Tracera, LLC.
Crisel received a Master of Business Administration in finance and entrepreneurship from Purdue University's Krannert School of Management and a Bachelor of Science in chemistry from Indiana University.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at http://www.astellas.us/. You can also follow us on Twitter at @AstellasUS, Facebook at http://www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.